![]() ![]() LBA51 KEYNOTE-024 5-year OS update: First-line pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score 50. The 2-year overall survival rate was 51.5, which was a breakthrough for NSCLC patients without EGFR/ALK mutation. KEYNOTE-024 Study Design (NCT02142738) International, randomized, open-label, controlled, phase 3 trial Adapted from Brahmer JR, et al. ![]() The median PFS and OS of the PM group were 10.0 and 30.0 months, respectively. The data come from Merck’s Keynote-024 trial, which nabbed Keytruda a solo nod in first-line NSCLC just a couple weeks after the New Jersey drugmaker presented results at ESMO’s 2016 confab. Recently, updated analysis of KEYNOTE-024 showed that PM continued to provide remarkable clinical outcomes. RELATED: Merck's Keytruda wins coveted first-line lung cancer nod, cementing rise 'from laggard to leader' Join millions of residential, public sector & business customers who use Constellation as their trusted electricity & natural gas supplier. “If you look at the percentage of patients who actually finished two years of therapy with Keytruda … 80% of those patients were alive at five years, and about half of those patients had not required any subsequent therapies,” he said. “I think it’s tremendously encouraging for patients that are facing a lung cancer diagnosis to be able to think about living for five years or longer from the time they’re diagnosed,” Scot Ebbinghaus, Merck VP of clinical research, said.īefore Keytruda hit the scene, the five-year survival mark in this patient group “was in the ballpark of 5%,” he noted.Īnd there was another feature of the data set Ebbinghaus pointed to as “remarkable.” Keytruda monotherapy also clocked a median response lasting 29.1 months, nearly five times longer than chemo’s 6.3 months, according results presented Monday at the European Society for Medical Oncology’s virtual annual meeting. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |